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Summary.-Misonidazole (MISO) is a nitroimidazole drug currently undergoing
clinical trials as a radiosensitizer of hypoxic tumour cells. The drug is also toxic to
such cells, probably because of metabolic activation of the nitro group under hypoxia.
The metabolic fate of 14C-labelled MISO is examined, using hypoxic mammalian
(CHO) cells in vitro. Organic-soluble and acid-soluble metabolites are formed, and
radioactivity is bound to macromolecules. Theorganic-soluble products areseparated
by TLC and HPLC. Evidence is presented to show that one of the metabolites is
hydroxylamino-misonidazole. The significance of metabolic nitroreduction is
discussed.
THE NITROIMIDAZOLE DRUG misonid-
azole (MISO) is an effective radiosensitizer
of hypoxic mammalian cells. It is hoped
that MISO, or a similar compound, will
overcome the radioresistance of tumours
that contain hypoxic cells. Clinical trials
are under way. It appears, however, that
the usefulness ofMISO may be limited by
its production ofdose-limiting side effects,
such as peripheral neuropathy (Urtasun
et al., 1977; Dische et al., 1978; Wasser-
man et al., 1980).
MISO is selectively toxic to hypoxic cells
in vitro, even in the absence of radiation
(Moore et al., 1976; Hall & Roizin-Towle,
1975). For example, exposures to MISO
which inactivate 9900 of cells under
hypoxic conditions have no observable
effect on aerobic cells. Hypoxic cells
accumulate radioactive metabolites of
MISO after exposure to labelled drug;
aerobic cells do not (Taylor & Rauth,
1978; Wong et al., 1978). This supports
the idea that hypoxic toxicity may result
from the formation of reactive nitro-
reduction products (Varghese et al., 1976;
Josephy et al., 1978; Taylor & Rauth,
1978). Furthermore ascorbic acid, a re-
ducing agent which enhances the produc-
tion of such metabolites (Taylor & Rauth,
1980a,b), greatly increases the hypoxic
toxicity of MISO (Josephy et al., 1978).
Separation of MISO metabolites has
been achieved by paper chromatography
(Varghese et al., 1976). However, the
efficiency of this technique is inferior to
that of thin-layer chromatography (TLC)
and high-pressure liquid chromatography
(HPLC); the procedure is also much
slower. Paper chromatography provided
some evidence for co-chromatography of
certain metabolites with the products of
zinc reduction of MISO (Varghese et al.,
1976) but conclusive identification of the
cellular products has not yet been pre-
sented.
Recently we have studied the reduction
of MISO by the hypoxanthine/xanthine
oxidase system under hypoxia (Josephy
et al., 1981). A single major product is
formed, which stoichiometry and mass
spectroscopy suggest is the hydroxyl-
amine derivative of MISO. Analogous
results have been obtained by radiation-
chemical reduction of the drug (Whillans
& Whitmore, 1980). In this paper we
examine the metabolism of MISO by
hypoxic Chinese hamster ovary (CHO)
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cells, and present evidence for the forma-
tion of hydroxylamino-misonidazole. TLC
and HPLC were used to separate the
products.
MATERIALS AND METHODS
Che,micals. Misonidazole was a gift of Dr
C. Smithen, Roche Products Ltd, Welwyn
Garden City. 14C-MISO, labelled at the 2
position of the imidazole ring (sp. act. 9-2
pCi/mg) was also provided by Dr Smithen.
3H-MISO (sp. act. 14 1uCi/mg) was a gift of
Dr D. Chapman, Cross Cancer Institute,
Edmonton, Alberta, Canada. Purity of both
radiolabelled MISO preparations was checked
by chromatography, using the systems de-
scribed below. Radioactive impurities were
less than 0.1% for each preparation. All
solvents were HPLC grade.
Chromatography. - Thin-layer chromato-
graphy was performed on XVhatman silica-gel
plates with pre-absorbent layers, Type
LK5DF. After application of the sample, the
plate was developed in 1:1 acetone/methanol.
The dried plate was autoradiographed w%ith
Kodak X-OMAT-R X-ray film.
The high-pressure liquid chromatography
used a Spectra-Physics SP 8000 chromato-
graph in isocratic mode. System A was as
follows: Column: Wlhatman ODS (reversed-
phase) 416 mm x 25 cm; mobile phase: 10mM
acetate buffer (pH 4 5) flow rate: 2-5 ml/min.
System B was as follows: Column: Whatman
PAC (polar amino-cyano bonded phase)
4 6 mm x 25 cm; mobile phase: ethyl acetate/
methanol (63%/37%); flow rate: 2-5 ml/min.
Column temperature X as maintained at 35°C
in both systems. A loop injector (50 ,tl) was
used. Fractions were collected in vials and
counted w%ith 5 ml scintillation cocktail
(ACS, Amersham) in a Beckman LS-330
scintillation counter.
Enzymatic reduction. Reduction of MISO
bythehypoxanthine/xanthine oxidase system
wNas performed as described by Josephy et al.
(1981) except that 3H-MISO was used. The
reduced product was lyophilized to dryness,
resuspended in methanol. filtered and stored
in the freezer until use.
Metabolism studies. Detection of cellular
inetabolites of MISO is hampered by several
factors: the low yield of organic-extractable
metabolites (see below), limited activity of
the radiolabelled drug, limited capacity of
analytical HPLC columns. Recovery of
metabolites wasu maximized by the use of
dense cell suspensions. CHO cells were grown
in suspension culture, in a medium supple-
mented with 10% foetal calf serum, as
described previously (Josephy et al., 1978).
Cells were diluted daily to about 7 x 104 cells/
ml, except for the final 24 h before an experi-
ment, when they were allowed to reach
5 x 105 cells/ml. Cells (3 x 108) A-ere harvested
by centrifugation and spun to form a pellet of
about 1 ml. The pellet was then resuspended
in of medium containing 14C-MISO to give a
total volume of2 ml and a drug concentration
of 0-38 mm. This concentration corresponds
to the plasma concentration achieved in
clinical trials, following oral administration
of a dose of about 0-2 mmol/kg (Workman.
1980). At zero time the tube was transferred
to a 37°C water bath. Water-saturated 02-
free N2 was flowed over the suspension
throughout the experiment. The suspension
wvas vortexed occasionally to prevent sedi-
mentation andadherence ofthe cells. Samples,
each 0 3 ml, were removed shortly after zero
time (within 2 min) and at each hour up to
3 h. The samples were then processed accord-
ing to the scheme shown in Table I. Each
sample was added to 1-7 ml distilled H20 and
sonicated for 10 sec using a Branson WT-350
cell disruptor with microtip. An aliquot of
the sonicate was dissolved in 05 ml of 2M
NaOH, neutralized with acetic acid and
counted to determine total activitv. The
remainder of the sonicate wras frozen and
lyophilized to dryness. The dry residue was
resuspended with ethyl acetate/methanol
(63%/37%), spun (5 min at 800 rev/min), and
the supernatant decanted. This procedure
wNas repeated x 3; the supernatants were
combined and evaporated in a Buchler vortex
evaporator at 30°C. The dry samples wNere
stored at - 15°C until chromatographed. The
samples were not stored more than one week
before chromatography. No change in
chromatographic profiles wvas observed during
storage.
Pellets.-In preliminary experiments, we
studied the pellets remaining after the above
extraction. The pellets contained acid-
soluble activity which rose wvith time of
incubation to -5000 of total activity, and
acid-insoluble activity rising from 0 to - 10%
oftotal activity. Presumably, these represent
MISO metabolites that are bound to small
molecules and macromolecules respectively
(Varghese & Whitmore, 1980b). To quanti-
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TABLE I Scheme ofSample Treatment
SAMPLE (0 3 ml, 4-5 X 17Ocells)
Sonicate
DISRUPTED CELLS
Lyophiliz
DRY RESIDUE
ORGANIC-INSOLUBLE MATERIAL
Extract with
Methanol/TCA
(10 times; combine extracts)
- remove aliquot to determine
total radioactivity
Extract with ethyl acetate/methanol
(3 times; combine extracts)
ORGANIC-SOLUBLE MATERIAL
Dry; resuspend in 1 ml methanol;
count aliquot; remove aliquot for
TLC
Dry; resuspend in acetate
buffer for HPLC
ORGANIC-INSOLUBLE, ACID-SOLUBLE MATERIAL
Count aliquot
PELLET - solubilize in NaOH and count
tate this binding, the pellets were treated as
follows. The pellet was carefully rinsed into
a cone of filter paper (Whatman No. 1) and
wrashed with 10 successive 2ml aliquots of a
mixture of equal volumes of methanol and
20% trichloracetic acid (TCA). Further
washing did not extract additional radio-
activity. An aliquot of the filtrate was
counted to determine total extractable
activity. Finally, the washed pellet was
dissolved in 2 ml of 2M NaOH with gentle
heating. The sample was neutralized with
acetic acid and counted. The recovery of
total initial radioactivity in the 3 fractions
was 70-80%, due to losses in handling.
Chromatography.-The dried supernatants
from the initial extraction into ethyl acetate/
methanol were dissolved in 1 ml methanol,
and an aliquot counted to determine total
activity. Aliquots (50 ,ul) wrere applied to
TLC plates as described above. The plates
were developed immediately and autoradio-
graphed. The remainder of the supernatant
was evaporated, and the residue was re-
suspended in 125 ,u acetate buffer. The
sample was then spun for 5 min in an Eppen-
dorf Model 5412 centrifuge to separate the
water-soluble supernatant from the insoluble
precipitate (presumably lipid). An aliquot of
the supernatant was injected into HPLC
System A. Fractions (100 x 0 5 ml) were
collected and counted.
Dual-label chromatography. - Preliminary
experiments demonstrated that a cellular
metabolite of MISO had similar chromato-
graphic properties to the major product of
445P. D. JOSEPHY, B. PALCIC AND L. D. SKARSGARD
hypoxanthine/xanthine oxidase reduction.
The identity of the cellular and enzymatic
products was proved by dual-isotope label-
ling, thus permitting the separation of-both
samples in a single HPLC injection. Co-
chromatography was verified in the two
different HPLC systems, as follows. 3H-
MISO was reduced enzymatically as de-
scribed. The cell pellet sample (14C-MISO)
was taken at 2 or 3 h and treated as described
above. After the organic-soluble material was
resuspended in methanol, an aliquot of the
enzymatic reduction mixture was added, in
an amount chosen to give a similar number
of 14C and 3H counts in the product peak.
The dual-label mixture was evaporated and
resuspended in acetate buffer (HPLC System
A) or ethyl acetate/methanol (HPLC System
B). In the former case fractionation was as
described above. In the latter System, 200
0-5ml fractions were collected and counted.
RESULTS
Cell samples were fractionated into 3
extracts according to the above methods:
the organic-soluble fraction (extracted
with ethyl acetate/methanol), the acid-
soluble fraction (extracted with methanol/
TCA), and the acid-insoluble material
(pellet). Fig. 1 shows the distribution of
total sample radioactivity between these
ORGANIC
insoluble
ACID soluble
I
vu I x 3 u Al
INCUBATION TIME (H)
FeIG. 1.-Distribution of radioactix-ity: CHO
cells exposed to 14C-MJISO. CHO cells
were incubated under hypoxia witlh 14C_
MISO for the times indicated, as described1
in text. Samples were dried and extracted
withl ethyl acetate/methanol (3 x 2 ml)
and methanol/TCA (10 x 2 ml). The total
activity in the organic-soluble, acid-
soluble, and insolthble fractions is shown.
FiG. 2. TLC analysis of MISO metabolites.
CHO cells were incubated un(ler hlypoxia
With 14C-MISO for up to 3 h. Organic-
soluble metabolites were separatedl by
TLC as (kescribedt in text. Samples were
run on a single pre-channelle(d TLC plate,
which was then autoradiographed on Kodak
X-ray film for 10 days. 0 h represents
2 min incubation. MISO is in(icate(1 by
the letter M. Dashed lines mark Rf = 0
and Rf= 1.
ORGANIC
soluble
- so
m
0
R. -.
, 40
U.,
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fractions. As a function of incubation
time, organic-soluble activity is converted
to organic-insoluble products, most of
which are acid-soluble; a smaller amount
is associated with the pellet. Even after all
free MISO has disappeared (about 3 h
incubation) the percentage of radio-
activity associated with the pellet is less
than 10% of total. Further incubation
beyond 3 h produced little change in the
distribution.
The nature of the acid-soluble material
has not been studied in detail. These
metabolites are highly polar (Rf almost
zero on TLC) and may include ionic con-
jugates such as glucuronides or sulphates.
The pellet contains activity bound (prob-
ably covalently) to nucleic acid and pro-
tein. Similar results have been obtained
both in vitro and in vivo (Varghese &
Whitmore, 1980a).
The organic-soluble fractions obtained
50
FRACTION
a
100
c
FRACTION
at successive times were further studied
by TLC and HPLC as described in
Methods. The results of TLC autoradio-
graphy are shown in Fig. 2. MISO (Rf=
0.78) is depleted by about 50% in 1 h and
completely metabolized in 3 h. This corres-
ponds to the conversion of about 105
molecules/sec/cell. Several metabolites of
MISO can be resolved, all having much
lower Rf than MISO itself. This is in agree-
ment with the general pattern of metabo-
lism to more polar derivatives.
The results of reversed-phase HPLC
analysis are shown in Fig. 3. These data
parallel the results obtained by TLC:
MISO (which is eluted between Fractions
60 and 80) is depleted during incubation
and converted to a variety of more polar
products (shorter retention times). After
incubation for as little as 2 min (Fig. 3A)
two products are detectable. After lh
incubation a complex pattern of metabo-
b
2r
1K
0
..
50
FRACTION
d
100
FIG. 3. HPLC analysis of MISO metabolites. CHO cells were incubated under hypoxia wlith 14C-
AIPSO ancl extracted as described in text. Samples were injected into HPLC System A (reversed-
plhase column). Chiromatograms show ct/min/fraction (0 5 ml) in thousands. Incubation time's
were: a, 2 mili; h, 1 h; c, 2 1h; (l, 3 I.
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F.IG. 4. HPLC comparisoin of cellular an(d enzymatic pro(lucts of MlISO. CHO cells were inicubated
un(ler liypoxia w-itlh 'MISO (14C label) as (lescribe(l in text. Extracted samples were combined with
aliquots of re(lucedI MISO (3H label) prepare(d by xanthine-oxidase-catalysed reduction (see text).
Combinedl samples were run in (a) HPLC System A (reversed-phase column) or (b) System B
(polar-bonded-phase column). Fractions were collected, counted for 3H and 14C activity, aindl
corrtecteil for backgrouunid( an(d spillov-er. 3H (lata are offset vertically for clarity, andl sbown as
broketn lines. a: 21i incuibation (same exp. as in Fig. :3(c)). b: 3h incubation (separate experiment).
lite peaks is seen. As with TLC results,
further incubation affects the peak heights,
but the pattern changes little. The largest
peak is found at or near Fraction 21. This
component was shown to co-chromato-
graph with the product of xanthine-
oxidase-catalysed reduction of MISO,
which is believed to be hydroxylamino-
misonidazole. This was demonstrated by
the dual-label technique described in
Methods. Results are presented in Fig. 4.
The enzymic reduction was not carried to
completion, so the extracted material
contains both 3H-MISO and 3H-hydroxyl-
amino-misonidazole as markers. These
markers gave peaks in Fractions 52 and 18
respectively (System A) and 15 and 60
respectively (System B). In both systems,
a major peak of 14C activity coincides with
the enzymically reduced product. The
material in this peak was collected from a
repeat run in System B, concentrated, and
run on TLC. Fractions were scraped,
eluted with methanol and counted. Again,
14C and 3H activity ran together (data not
shown).
IDISCUSSION
The medical application of nitroimid-
azoles has stimulated work on the chemis-
try and pharmacology of these com-
pounds. In particular, the nature of the
products obtained by chemical reduction
of MISO has been investigated. Varghese
et al. (1976) reduced MISO with zinc dust
under vigorous conditions (lh reflux in
aqueous ethanol). Several products were
detected by paper chromatography, but
none has been conclusively identified. WNe
have found that this procedure yields a
very large number of products, including
coloured and fluorescent compounds that
may be separated by TLC (unpublished
observations). We have also shown that
zinc reduction under milder conditions (at
room temperature, in the presence of
CaC12) yields the azo and azoxy deriva-
tives of misonidazole. These were separ-
ated by preparative column chromato-
graphy and prepared in quantity (Josephy
et al., 1980). Recently, Varghese &
Whitmore (1 980a, b) described another
procedure, reduction with zinc at 37'C in
the presence ofNH4Cl. Again, several pro-
ducts resulted, apparently including the
azo, azoxy, and possibly, hydroxylamine
derivatives.
The enzymatic (Josephy et al., 1981)
and radiation-chemical (Whillans & Whit-
more, 1980) reductions of MISO yield a
single major product with 4-electron
stoichiometry. Mass spectroscopy sug-
gests that this is hydroxylamino-misonid-
azole (m/e= 187) but it has not yet been
2
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TABLE II-Proposed scheme of misonidazole metabolism
conjugation polar metabolites
R-NO02 demethylation (intact nitro group)
reduction (02 inhibits or reverses)
R-N=0
(unstable?) Binding to macromolecul
Toxicity?
R-NHOH polar conjugation
reduced
c
metabolites -NTT
isolated in sufficient quantity for further
characterization. This may be due to dis-
proportionation of the product, which is
known to occur with aromatic hydroxyl-
amines (Wardman, 1977).
In this paper, we have shown that a
metabolite of MISO, produced in hypoxic
cells, is identical to the enzymic product.
This metabolite can be detected after a
very brief exposure to MISO (Fig. 3a) and,
after the disappearance of the parent
drug, it remains the major organic-
soluble metabolite.
The in vitro metabolism of 14C-MISO
has been studied previously (e.g. Taylor &
Rauth, 1978, 1980a, b; Varghese et al.,
1976; Whitmore et al., 1978). In the pre-
sent paper, however, we have used labelled
drug with more than 1-00-fold specific
activity. Also, we have separated organic-
soluble material from the cell extracts
before chromatography. The organic-
insoluble, acid-soluble material represents
at least half the metabolite activity; since
this material is very polar, it would elute
early on a reversed-phase column, and
might obscure the metabolites seen in
Figs 3 and 4. We consider it unlikely that
the reduced product identified in this
paper corresponds to one of the peaks
(e.g. P1, P2) seen in paper chromato-
graphy of crude extracts of CHO cells
(Taylor & Rauth, 1978).
WVe believe that our results are con-
sistent with the scheme shown in Table II,
which outlines the pathways of MISO
metabolism. This scheme is similar to that
presented by Taylor & Rauth (1980b).
MISO may be converted to polar deriva-
tives without reductive activation, e.g.
by demethylation. This pathway is of
clinical importance (Flockhart et al., 1978).
Reductive activation proceeds in hypoxia,
and 02 inhibits this pathway, probably by
reoxidation of the initial one-electron
reduction product of MISO, the nitro-
anion free radical (Mason & Holtzman,
1975; Sealy et al., 1978). The first rela-
tively stable nitroreduction product to be
formed is probably the hydroxylamine,
the nitroso compound being reduced too
rapidly to be detected. An analogous
mechanism has been demonstrated for
nitrobenzene reduction (Wardman 1977,
p. 371). The hydroxylamine may be fur-
ther reduced to the amine, which is prob-
ably a urinary excretion product in man
(Flockhart et al., 1978). According to this
scheme, one or more reactive inter-
mediates formed during the reduction of
MISO may be responsible for binding to
nucleic acid and protein, and probably
also for the toxic and mutagenic pro-
perties ofthe drug. It is not clear at which
level in the reduction pathway this toxic
species is formed. Its identity has proved
elusive, owing to the difficulty ofisolating
the intermediate reduction products. In-
les
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deed, the formation of azo and azoxy
dimers during chemicalreduction (Josephy
et al., 1980) is probably a consequence of
the reactivity ofintermediates such as the
nitroso compound.
Finally, it should be noted that the pro-
cesses shown in Table II are not mutually
exclusive; for example, demethylation
could be followed by reduction, or reduc-
tion by conjugation. Indeed such "twice-
metabolized" products may be quantita-
tively predominant, particularly in the
organic-insoluble, acid-soluble fraction.
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